cGMP Plasmid DNA Manufacturing Facility, Thermo Fisher, California, USA
Thermo Fisher Scientific Inc., the global leader in serving science, has opened a new cGMP plasmid DNA manufacturing facility in Carlsbad, California.
The modern Thermo Fisher facility will serve to meet the rapidly growing demand for plasmid DNA-based therapies and vital mRNA-based vaccines.
New Plasmid DNA Manufacturing Facility
Plasmid DNA is increasingly used as a therapeutic agent in gene therapies and certain vaccines. Its benefits, including weak immunogenicity, increased safety and ease of manufacture, have drastically increased demand for materials and manufacturing capacity worldwide.
Marc N. Casper, chairman, president and chief executive officer, Thermo Fisher Scientific commented:
“Demand for commercial plasmid DNA is outpacing supply as the development of transformative gene therapies and vaccines accelerates globally. Investments in state-of-the-art manufacturing such as this ensure that our customers have reliable access to the high-quality materials and capabilities that have become vital for the production of these new lifesaving medicines and the patients in need.”
Meeting global demand for cell and gene therapies and vaccines
The ultra-modern 67,000-square-foot facility, located on Thermo Fisher’s Carlsbad campus, is part of an investment strategy to ensure customers can reliably meet the growing global demand for cell and gene therapies and vaccines.
With its fully integrated development, supply chain, and manufacturing capabilities, which include viral vector services in Cambridge, Lexington and Massachusetts, and Alachua in Florida, as well as Gosselies and Seneffe, Belgium, a new cell therapy manufacturing facility in Princeton, New Jersey, and a new cryocenter in Weil am Rhein, Germany to support clinical trials, Thermo Fisher customers can progress rapidly from discovery to clinical to patient impact.
The expansion in Carlsbad also benefits the growing life sciences ecosystem in California, and Thermo Fisher will add more than 150 new roles as production scales up. To celebrate the opening of the new facility, Thermo Fisher hosted a ribbon-cutting ceremony on July 15th with local government officials including U.S. Representatives Mike Levin and Scott Peters and Carlsbad City Mayor Matt Hall.
U.S Representative Mike Levin said:
“This expansion in Carlsbad is exciting, bringing new jobs and revenue to our district, while also advancing San Diego County’s reputation as a hub for innovation. Their work helps tackle many of the world’s greatest challenges and builds healthier, more sustainable communities.”
U.S. Representative Peters commented:
“I’m thrilled that this expansion will add jobs, advance medical services manufacturing capabilities in San Diego and California and further bolster our regions’ leadership in scientific innovation.”
The Mayor of Carlsbad Matt Hall added:
“We’re pleased that Thermo Fisher continues to expand its footprint in Carlsbad, and their investment will contribute greatly to our community’s economic development and our reputation as a home to innovators who are improving health and medicine globally.”
To learn more about Thermo Fisher’s new cGMP Plasmid DNA manufacturing facility, please visit www.thermofisher.com/patheon. Open positions can be found at jobs.thermofisher.com.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the global leader in serving science, with annual revenue exceeding $30 Billion. The company’s main goal is to enable it’s customers to make the world healthier, cleaner and safer. Whether companies need to accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and therapies or increase productivity in their laboratories, Thermo Fisher is here to support them.
With its global team of more than 80,000 colleagues, Thermo Fisher Scientific delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through it’s industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.
For more information, please visit www.thermofisher.com.
Advertisement
Latest Projects
- Plasma-Derived Therapies Manufacturing Plant, 2030, Takeda, Osaka, Japan
Takeda plans to invest approximately 100 Billion Yen ( 762,330,000 Million USD) to construct a new manufacturing plant for plasma-derived - Continuous Manufacturing Line for Oral Solids, WuXi STA, China
WuXi STA, a subsidiary of WuXi AppTec, opened the doors of its first pharmaceutical product Continuous Manufacturing (CM) line for - BioNTech Boosts Autonomy with In-House Plasmid DNA Manufacturing Facility in Marburg
The construction of BioNTech’s first in-house plasmid DNA processing plant in Marburg, Germany, has now been completed, the company announced - Plasmid DNA Manufacturing Facility, Catalent, Gosselies, Belgium
The opening of Catalent’s new ultra-modern, commercial-scale plasmid DNA (pDNA) manufacturing facility in Gosselies, Belgium was announced on the 26th - Pfizer to Acquire Abzena’s North Carolina Biologics Manufacturing Facility
Pharma giant Pfizer Inc. and the Global Partner Research Organization (PRO) for integrated bench-to-market solutions for biologics and bioconjugates, Abzena, announced - Moderna and UK Government Ink Partnership to Build mRNA Vaccine Research Facility
Moderna Inc will make investments in mRNA research and development (R&D) in the UK and construct a cutting-edge facility for
